23andMe Announces CEO’s Take-Private Proposal
01 8월 2024 - 9:00PM
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and
biopharmaceutical company, has received a preliminary non-binding
indication of interest from Anne Wojcicki, Chief Executive Officer,
Co-Founder, and Chair of the Board of Directors of 23andMe, to
acquire all of the outstanding shares of 23andMe not owned by her
or her affiliates or any other stockholder that she invites to roll
over their shares for cash consideration of $0.40 per share of
Class A Common Stock or Class B Common Stock (the “Proposal”). Ms.
Wojcicki announced the Proposal on July 31, 2024 in a
Schedule 13D filing with the Securities and Exchange Commission.
The Special Committee previously formed by the Board of
Directors of 23andMe is carefully reviewing and evaluating the
Proposal and is committed to acting in the best interests of
23andMe and its shareholders.
There can be no assurance that the foregoing will result in any
particular outcome.
The Special Committee has engaged Wells Fargo as its financial
advisor and Dechert LLP as its legal advisor.
About 23andMe
23andMe is a genetics-led consumer healthcare and
biopharmaceutical company empowering a healthier future. For more
information, please visit www.23andMe.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements, other than statements of historical fact,
included or incorporated in this press release, including
statements regarding 23andMe’s strategy, are forward-looking
statements. The words "believes," "anticipates," "estimates,"
"plans," "expects," "intends," "may," "could," "should,"
"potential," "likely," "projects," “predicts,” "continue," "will,"
“schedule,” and "would" or, in each case, their negative or other
variations or comparable terminology, are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. These forward-looking
statements are predictions based on 23andMe’s current expectations
and projections about future events and various assumptions.
23andMe cannot guarantee that it will actually achieve the plans,
intentions, or expectations disclosed in its forward-looking
statements and you should not place undue reliance on 23andMe’s
forward-looking statements. These forward-looking statements
involve a number of risks, uncertainties (many of which are beyond
the control of 23andMe), or other assumptions that may cause actual
results or performance to differ materially from those expressed or
implied by these forward-looking statements. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company’s filings with the Securities and Exchange Commission,
including under Item 1A, “Risk Factors” in the Company’s most
recent Annual Report on Form 10-K, as filed with the Securities and
Exchange Commission, and as revised and updated by our Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K. The
statements made herein are made as of the date of this press
release and, except as may be required by law, 23andMe undertakes
no obligation to update them, whether as a result of new
information, developments, or otherwise.
Contact: press@23andme.com
23andMe (NASDAQ:ME)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
23andMe (NASDAQ:ME)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024